

Bulletin from the annual general meeting 2025 in SynAct Pharma AB

Today, on 27 May 2025, the annual general meeting in SynAct Pharma AB ("Company") was held in Stockholm. Below is a summary of the most important resolutions from the annual general meeting of the Company.

Resolution on adoption of accounts and allocation of the Company's result

The annual general meeting resolved to adopt the income statement and balance sheet, and the consolidated income statement and consolidated balance sheet. The annual general meeting further resolved to allocate the Company's result in accordance with the proposal from the Board of Directors, meaning that no dividends are paid and that the available funds are carried forward.

Discharge from liability for the members of the Board of Directors and the CEO

The annual general meeting resolved to discharge all persons who have been members of the Board of Directors or CEO of the Company during 2024 from liability.

Number of members of the Board of Directors

The annual general meeting resolved that the Board of Directors should consist of four ordinary board members and no deputy board members.

Remuneration for the Board of Directors and the auditors

The annual general meeting resolved that board remuneration shall be paid with SEK 300,000 to the Chairman of the Board of Directors and with SEK 200,000 to each of the other board members who are not employed by the Company. It is further resolved that remuneration for committee work, if such committees are established by the Board of Directors, shall be paid with SEK 50,000 to the Chairman of the Audit Committee, with SEK 25,000 to each of the other members of the Audit Committee, with SEK 25,000 to the Chairman of the Remuneration Committee, and with SEK 15,000 to each of the other members of the Remuneration Committee.

The annual general meeting further resolved that the remuneration to the auditor shall be paid in accordance with customary norms and approved invoice.

Election of the Board of Directors

The annual general meeting resolved to re-elect Anders Kronborg, Sten Scheibye and Sten Sørensen and to elect Jeppe Ragnar Andersen as members of the Board of Directors for the period until the next annual general meeting. Anders Kronborg was re-elected as Chairman of the Board of Directors.

Election of audit firm

KPMG AB was re-elected as audit firm. KPMG AB has announced that the authorized public accountant Linda Bengtsson will continue to be the auditor in charge.

Remuneration report

The annual general meeting approved the Board of Director's proposal for the remuneration report.

Resolution on instruction and charter for the Nomination Committee

The annual general meeting resolved to adopt the instruction and charter for the Nomination Committee in accordance with the proposal by the Board of Directors.

Resolution on guidelines for remuneration to senior executives

The annual general meeting resolved to adopt guidelines for remuneration to senior executives in accordance with the proposal by the Board of Directors.

Authorization to resolve on new issues

The annual general meeting resolved to authorize the Board of Directors to, on one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders' preferential rights, and with or without provisions regarding payment in kind or through set-off or other provisions, to resolve to issue new shares, convertibles and/or warrants. The increase of the share capital may correspond to a dilution of a maximum of 20 percent of the share capital at the time of the first use of the authorization. The reason for deviating from the shareholders' preferential rights shall be permitted is to enable the Company to raise working capital, to execute acquisitions of companies or operating assets, to be able to expand the ownership base with owners of strategic importance as well as to enable issues to industrial partners within the framework of partnerships and alliances.

To the extent that the issue is made with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

For the Company's full instruction and charter for the Nomination Committee as well as the full guidelines for remuneration to senior executives as described above, please refer to the Company's website <https://synactpharma.com/>.

Stockholm 27 May 2024

SynAct Pharma AB

For further information, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: <https://synactpharma.com/>.

Attachments

[Bulletin from the annual general meeting 2025 in SynAct Pharma AB](#)